Legend Biotech Surpasses EPS Expectations despite Revenue Miss

Legend Biotech Corporation (NASDAQ: LEGN) reported strong third-quarter 2025 financial results, exceeding analysts’ expectations for earnings per share while slightly falling short of projected revenue. The company’s cell therapy business continues to thrive, propelled by the ongoing demand for its flagship product, CARVYKTI®. This success despite a slight revenue shortfall highlights Legend Biotech’s ability to manage costs and optimize operations. 2025’s Q3 results showcase positive trends in financial performance.